{"title":"COVID-19 vaccines and neurological disorders: A narrative review of immune responses and adverse reactions.","authors":"Mehran Joodaki, Farhad Seif, Azadeh Afzalnia, Nikoo Emtiazi, Mona Merati Shirazi, Behnaz Ashtari, Seyed Mohamad Hosseinian, Nasrin Hosseini","doi":"10.3934/Neuroscience.2025013","DOIUrl":null,"url":null,"abstract":"<p><p>COVID-19 vaccines have been effective in providing strong immunity within a relatively short time frame, significantly reducing both the severity of the disease and associated mortality. However, post-vaccination complications, particularly neurological disorders, have been reported. Among the more frequently documented neurological complications are acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), transverse myelitis (TM), optic neuritis (ON), Bell's palsy (BP), and Guillain-Barré syndrome (GBS). The precise role of COVID-19 vaccines in triggering the onset or relapse of these conditions remains uncertain. Immunological processes involving cytokines, chemokines, antibodies, and immune cells are believed to contribute to the pathogenesis of these neurological side effects. This review examines the immune responses triggered by COVID-19 vaccines and their potential role in the development of such complications. Despite reports of neurological side effects, these cases remain rare, and the overall benefits of vaccination in curbing the pandemic and preventing severe illness far exceed the risks. It is vital to sustain the progress of global vaccination efforts while continuously evaluating the risk-benefit ratio, particularly for individuals with underlying conditions. Ongoing research and surveillance are crucial for creating safer vaccines and identifying individuals who may be more susceptible to adverse reactions, ensuring broader protection against COVID-19.</p>","PeriodicalId":7732,"journal":{"name":"AIMS Neuroscience","volume":"12 2","pages":"222-249"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287643/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/Neuroscience.2025013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
COVID-19 vaccines have been effective in providing strong immunity within a relatively short time frame, significantly reducing both the severity of the disease and associated mortality. However, post-vaccination complications, particularly neurological disorders, have been reported. Among the more frequently documented neurological complications are acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), transverse myelitis (TM), optic neuritis (ON), Bell's palsy (BP), and Guillain-Barré syndrome (GBS). The precise role of COVID-19 vaccines in triggering the onset or relapse of these conditions remains uncertain. Immunological processes involving cytokines, chemokines, antibodies, and immune cells are believed to contribute to the pathogenesis of these neurological side effects. This review examines the immune responses triggered by COVID-19 vaccines and their potential role in the development of such complications. Despite reports of neurological side effects, these cases remain rare, and the overall benefits of vaccination in curbing the pandemic and preventing severe illness far exceed the risks. It is vital to sustain the progress of global vaccination efforts while continuously evaluating the risk-benefit ratio, particularly for individuals with underlying conditions. Ongoing research and surveillance are crucial for creating safer vaccines and identifying individuals who may be more susceptible to adverse reactions, ensuring broader protection against COVID-19.
期刊介绍:
AIMS Neuroscience is an international Open Access journal devoted to publishing peer-reviewed, high quality, original papers from all areas in the field of neuroscience. The primary focus is to provide a forum in which to expedite the speed with which theoretical neuroscience progresses toward generating testable hypotheses. In the presence of current and developing technology that offers unprecedented access to functions of the nervous system at all levels, the journal is designed to serve the role of providing the widest variety of the best theoretical views leading to suggested studies. Single blind peer review is provided for all articles and commentaries.